PDCD1 and cervical cancer: Besides, the European Medicine Agency (EMA) approved Cemiplimab, a PD-1 specific antibody, in 2022 due to its significant enhancement in overall survival of cervical cancer (12.0 versus 8.5 months, HR = 0.69) (9).